|
DE3812225A1
(de)
|
1988-04-13 |
1989-10-26 |
Basf Ag |
Isoxazol(isothiazol)-5-carbonsaeureamide
|
|
BR9606546A
(pt)
|
1995-08-02 |
1998-07-14 |
Uriach & Cia Sa J |
Novas carboxamidas com atividade fungicida
|
|
DE69628705T2
(de)
|
1995-08-24 |
2004-05-13 |
Basf Ag |
Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
|
|
ATE228119T1
(de)
|
1998-04-15 |
2002-12-15 |
Pfizer Prod Inc |
Heterocyclische carboxamide
|
|
WO2002000651A2
(en)
|
2000-06-27 |
2002-01-03 |
Bristol-Myers Squibb Pharma Company |
Factor xa inhibitors
|
|
EP1501514B1
(en)
|
2002-05-03 |
2012-12-19 |
Exelixis, Inc. |
Protein kinase modulators and methods of use
|
|
EP1680411A2
(en)
|
2003-10-08 |
2006-07-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
|
|
CN101675928A
(zh)
|
2003-11-14 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
|
|
WO2005077373A2
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Treatment of gastro-esophageal reflux disease (gerd)
|
|
WO2005077345A1
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Compounds for the treatment of gastro-esophageal reflux disease
|
|
WO2006078287A2
(en)
|
2004-05-06 |
2006-07-27 |
Plexxikon, Inc. |
Pde4b inhibitors and uses therefor
|
|
SE0401969D0
(sv)
|
2004-08-02 |
2004-08-02 |
Astrazeneca Ab |
Piperidine derivatives
|
|
US20060100226A1
(en)
|
2004-09-10 |
2006-05-11 |
Sikorski James A |
2-Thiopyrimidinones as therapeutic agents
|
|
DE102004051277A1
(de)
|
2004-10-21 |
2006-04-27 |
Merck Patent Gmbh |
Heterocyclische Carbonylverbindungen
|
|
JP2006176443A
(ja)
|
2004-12-22 |
2006-07-06 |
Shionogi & Co Ltd |
メラニン凝集ホルモン受容体アンタゴニスト
|
|
JP2008543923A
(ja)
|
2005-06-22 |
2008-12-04 |
ファイザー・プロダクツ・インク |
ヒスタミン−３受容体アンタゴニスト
|
|
JP4822406B2
(ja)
|
2005-09-26 |
2011-11-24 |
ルネサスエレクトロニクス株式会社 |
表示制御駆動装置および表示システム
|
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
|
KR101394245B1
(ko)
|
2005-12-30 |
2014-05-14 |
에스케이바이오팜 주식회사 |
아이속사졸 유도체 및 이의 용도
|
|
WO2007086584A1
(ja)
|
2006-01-30 |
2007-08-02 |
Meiji Seika Kaisha, Ltd. |
新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
|
|
TW200815351A
(en)
|
2006-05-02 |
2008-04-01 |
Astrazeneca Ab |
Novel compounds
|
|
WO2008046072A2
(en)
|
2006-10-13 |
2008-04-17 |
The Board Of Regents Of The University Of Texas System |
Chemical inducers of neurogenesis
|
|
US8193225B2
(en)
|
2006-10-13 |
2012-06-05 |
The Board Of Regents Of The University Of Texas System |
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
|
|
EA200900573A1
(ru)
|
2006-10-20 |
2009-10-30 |
АйАрЭм ЭлЭлСи |
Композиции и способы для модуляции рецепторов c-kit и pdgfr
|
|
WO2008070739A1
(en)
|
2006-12-06 |
2008-06-12 |
Cytokinetics, Inc. |
Ksp activators
|
|
ES2379746T3
(es)
|
2007-06-29 |
2012-05-03 |
Sk Biopharmaceuticals Co., Ltd. |
Composición farmacéutica para la prevención y el tratamiento de la restenosis que comprende los derivados del isoxazol
|
|
US20090069288A1
(en)
|
2007-07-16 |
2009-03-12 |
Breinlinger Eric C |
Novel therapeutic compounds
|
|
JP2011511756A
(ja)
|
2007-08-02 |
2011-04-14 |
ナームローゼ・フエンノートチヤツプ・オルガノン |
Ｔｒｐｖ１モジュレータとしての５−フェニル−イソオキサゾール−３−カルボキサミド誘導体
|
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
US8236838B2
(en)
|
2008-04-21 |
2012-08-07 |
Institute For Oneworld Health |
Compounds, compositions and methods comprising isoxazole derivatives
|
|
US20090318429A1
(en)
|
2008-04-28 |
2009-12-24 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
|
|
JP2012516840A
(ja)
|
2009-02-04 |
2012-07-26 |
エム・エス・ディー・オス・ベー・フェー |
イソオキサゾール−５−カルボキサミド誘導体
|
|
BRPI1008974A2
(pt)
|
2009-03-11 |
2017-06-06 |
Kyorin Seiyaku Kk |
composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
|
|
PL2408750T3
(pl)
*
|
2009-03-20 |
2016-02-29 |
Vertex Pharma |
Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
|
|
GB0910003D0
(en)
|
2009-06-11 |
2009-07-22 |
Univ Leuven Kath |
Novel compounds for the treatment of neurodegenerative diseases
|
|
IN2012DN00352A
(https=)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
|
WO2011008931A2
(en)
|
2009-07-15 |
2011-01-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
|
|
US9212177B2
(en)
|
2009-08-05 |
2015-12-15 |
Versitech Limited |
Antiviral compounds and methods of making and using thereof
|
|
GB2474120B
(en)
|
2009-10-01 |
2011-12-21 |
Amira Pharmaceuticals Inc |
Compounds as Lysophosphatidic acid receptor antagonists
|
|
US8569899B2
(en)
|
2009-12-30 |
2013-10-29 |
Stmicroelectronics, Inc. |
Device and method for alignment of vertically stacked wafers and die
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
CA2796602A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
WO2012007500A2
(de)
|
2010-07-15 |
2012-01-19 |
Bayer Cropscience Ag |
Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
AU2012226890B2
(en)
|
2011-03-10 |
2016-10-06 |
Daiichi Sankyo Company, Limited |
Dispiropyrrolidine derivative
|
|
CA2736441A1
(en)
|
2011-04-06 |
2012-10-06 |
The Regents Of The University Of California |
Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
|
|
HUE047354T2
(hu)
*
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
|
RS56096B1
(sr)
*
|
2011-05-18 |
2017-10-31 |
Concert Pharmaceuticals Inc |
Deuterisani derivati ivakaftora
|
|
US9428490B2
(en)
|
2011-07-29 |
2016-08-30 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
US8623860B2
(en)
|
2011-12-30 |
2014-01-07 |
Boehringer Ingelheim International Gmbh |
Azetidine derivatives, pharmaceutical compositions and uses thereof
|
|
AU2013221420B2
(en)
|
2012-02-16 |
2017-07-13 |
Corteva Agriscience Llc |
Methods of producing sulfilimine compounds
|
|
UA110436C2
(en)
|
2012-03-06 |
2015-12-25 |
Zoetis Llc |
Antibacterial phenol compounds
|
|
WO2013146970A1
(ja)
|
2012-03-29 |
2013-10-03 |
第一三共株式会社 |
新規キノリン誘導体
|
|
ES2869701T3
(es)
|
2012-08-01 |
2021-10-25 |
United Therapeutics Corp |
Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina
|
|
EP2898072A1
(en)
|
2012-09-24 |
2015-07-29 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Restoration of the cftr function by splicing modulation
|
|
US9546176B2
(en)
|
2012-11-20 |
2017-01-17 |
Discoverybiomed, Inc. |
Small molecule bicyclic and tricyclic CFTR correctors
|
|
EP2922852A4
(en)
|
2012-11-20 |
2016-05-25 |
Discoverybiomed Inc |
SMALL MOLECULAR CFTR CORRECTORS
|
|
CN103833630B
(zh)
*
|
2012-11-21 |
2018-11-13 |
顶点制药（欧洲）有限公司 |
氘化cftr增效剂
|
|
EP2968285A4
(en)
|
2013-03-13 |
2016-12-21 |
Flatley Discovery Lab |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
MX365950B
(es)
|
2013-03-13 |
2019-06-19 |
Flatley Discovery Lab Llc |
Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
|
|
WO2014144860A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Correctors acting through msd1 of cftr protein
|
|
CA2903103C
(en)
|
2013-03-15 |
2020-06-09 |
Discoverybiomed, Inc. |
Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
|
|
US20160074374A1
(en)
|
2013-04-26 |
2016-03-17 |
Vertex Pharmaceuticals Incorporated |
Correctors acting through msd1 of cftr protein
|
|
WO2014180562A1
(en)
|
2013-05-07 |
2014-11-13 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
|
|
WO2014181287A1
(en)
|
2013-05-09 |
2014-11-13 |
Piramal Enterprises Limited |
Heterocyclyl compounds and uses thereof
|
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
|
US9920073B2
(en)
|
2013-10-04 |
2018-03-20 |
Drexel University |
Compositions useful for inhibiting HIV-1 infection and methods using same
|
|
WO2015138909A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
US9745292B2
(en)
|
2014-03-13 |
2017-08-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
|
EP3157917B1
(en)
|
2014-06-19 |
2020-03-18 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
|
WO2016054560A1
(en)
|
2014-10-02 |
2016-04-07 |
Flatley Discovery Lab |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
|
US10738011B2
(en)
|
2014-12-23 |
2020-08-11 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US10392378B2
(en)
|
2014-12-23 |
2019-08-27 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US10344023B2
(en)
|
2014-12-23 |
2019-07-09 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
US10548878B2
(en)
|
2015-07-24 |
2020-02-04 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods of increasing CFTR activity
|
|
US20190022071A1
(en)
|
2015-08-31 |
2019-01-24 |
Proteostasis Therapeutics, Inc. |
Methods of treating pulmonary diseases and disorders
|
|
BR112018007021B1
(pt)
|
2015-10-06 |
2024-01-09 |
Proteostasis Therapeutics, Inc |
Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
|
|
US20180369209A1
(en)
|
2015-12-22 |
2018-12-27 |
Proteostasis Therapeutics, Inc. |
Methods of treating pulmonary diseases and disorders
|
|
MA43775A
(fr)
|
2016-04-07 |
2021-05-05 |
Proteostasis Therapeutics Inc |
Analogues du ivacaftor conentant des atomes de silicium
|
|
US20190154661A1
(en)
|
2016-05-09 |
2019-05-23 |
Proteostasis Therapeutics, Inc. |
Methods of identifying cftr modulators
|
|
MA45397A
(fr)
|
2016-06-21 |
2019-04-24 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|